TY  - GEN
AU  - Postow,Michael A
TI  - Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse?
SN  - 1543-0790
PY  - 2018///0926
KW  - Antibodies, Monoclonal
KW  - therapeutic use
KW  - Antibodies, Monoclonal, Humanized
KW  - Chemotherapy, Adjuvant
KW  - methods
KW  - Combined Modality Therapy
KW  - Gene Expression Regulation, Neoplastic
KW  - Humans
KW  - Imidazoles
KW  - Immunotherapy
KW  - Interferon alpha-2
KW  - Interferon-alpha
KW  - Ipilimumab
KW  - MAP Kinase Kinase 1
KW  - antagonists & inhibitors
KW  - Melanoma
KW  - drug therapy
KW  - Nivolumab
KW  - Oximes
KW  - Prognosis
KW  - Programmed Cell Death 1 Receptor
KW  - Proto-Oncogene Proteins B-raf
KW  - Pyridones
KW  - Pyrimidinones
KW  - Randomized Controlled Trials as Topic
KW  - Recombinant Proteins
KW  - Recurrence
KW  - Skin Neoplasms
KW  - Survival Analysis
N1  - Publication Type: Journal Article
ER  -